Grüncef (Cefadroxil Monohydrate)

Grüncef is indicated for the treatment of several bacterial infections that are susceptible to cefadroxil. It is commonly prescribed by healthcare professionals for the following conditions:

• Uncomplicated skin and soft tissue infections such as cellulitis and impetigo
• Acute uncomplicated urinary tract infections caused by susceptible organisms
• Respiratory tract infections including pharyngitis, tonsillitis, and bronchitis
• Surgical prophylaxis in certain low‑risk procedures
• Infections where a first‑generation cephalosporin is appropriate based on culture results

Side effects of Grüncef vary in frequency and severity. Patients should be aware of both common and serious reactions.

Common

• Nausea or vomiting
• Diarrhea, which may be mild to moderate
• Abdominal discomfort or flatulence
• Headache
• Rash or mild skin redness
• Transient elevation of liver enzymes

Serious

• Severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome
• Clostridioides difficile‑associated colitis
• Significant liver injury (hepatitis, jaundice)
• Hematologic abnormalities like neutropenia or thrombocytopenia
• Acute interstitial nephritis
• Serum sickness‑like reactions

Before starting Grüncef, certain precautions should be considered to minimize risks:

• Assess for a history of hypersensitivity to cephalosporins, penicillins, or other beta‑lactam antibiotics
• Use with caution in patients with renal impairment; dosage adjustment may be required
• Monitor liver function tests in patients with pre‑existing hepatic disease
• Evaluate for gastrointestinal conditions that predispose to C. difficile infection
• Consider pregnancy and lactation status; category B indicates no proven risk but discuss with a clinician
• Review patient age, as elderly individuals may have increased susceptibility to adverse effects
• Ensure appropriate microbiological diagnosis to confirm susceptibility

Grüncef may interact with other medicines, affecting its efficacy or safety. Interactions are grouped by the level of concern.

Avoid

• Concurrent use with other nephrotoxic agents (e.g., aminoglycosides, vancomycin) that may increase kidney injury risk
• Combination with anticoagulants such as warfarin, which can enhance bleeding tendencies
• Use with probenecid, which can reduce renal clearance of cefadroxil and raise plasma levels

Use with caution

• Oral contraceptives, as antibiotics may reduce contraceptive effectiveness
• Diuretics, particularly loop diuretics, which may affect electrolyte balance
• Allopurinol, due to potential rash enhancement
• Antacids containing aluminum or magnesium, which could interfere with absorption
• Immunosuppressants like cyclosporine, requiring monitoring of drug levels